Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Examining the potential of Moonlake Therapeutics' sonelokimab in treating hidradenitis suppurativa (HS) with a focus on the recent Phase 2 MIRA data

Ticker(s): MLTX

Who's the expert?

Institution: Private Practice (Florida)

Dermatologist at Riverchase Dermatology & volunteer clinical associate professor at the University of Miami School of Medicine.
PI for several psoriasis trials; treats patients with scalp and body psoriasis and GPP.
Involved in clinical research with a specialty interest in psoriasis, vitiligo, and complex medical dermatology.

Interview Goal

This interview will focus on discussing the standard of care and the potential of sonelokimab (M1095) is an investigational ~40 kDa humanized Nanobody that inhibits the IL-17A/A, IL-17A/F, and IL-17F/F dimers being developed by Moonlake Therapeutics for the treatment of hidradenitis suppurativa (HS).

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.